Waldenström’s Macroglobulinemia

1. Front Matter

   Pages i-ix

   PDF

2. Tumor Cells and Microenvironment

   1. Front Matter

      Pages 1-1

      PDF

   2. Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment

      • Roger G. Owen, Andy C. Rawstron, Ruth M. de Tute

      Pages 3-19

   3. Waldenström’s Macroglobulinemia Immunophenotype

      • Noemí Puig, Enrique M. Ocio, Cristina Jiménez, Bruno Paiva, Jesús F. San Miguel, Ramón García-Sanz

      Pages 21-34

   4. Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis

      • Linda M. Pilarski, Jitra Kriangkum, Sophia Adamia, Helga M. Ogmundsdottir, Andrew R. Belch

      Pages 35-48

   5. Cytogenetics in Waldenström Macroglobulinemia (WM)

      • Florence Nguyen-Khac

      Pages 49-51

   6. Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia

      • Zachary R. Hunter, Guang Yang, Lian Xu, Xia Liu, Jorge J. Castillo, Steven P. Treon

      Pages 53-65

   7. Molecular Pathways in Growth and Survival: Epigenomics

      • Antonio Sacco, Michele Moschetta, Salomon Manier, Giuseppe Rossi, Irene M. Ghobrial, Aldo M. Roccaro

      Pages 67-71

   8. The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia

      • Efstathios Kastritis, Aldo Roccaro, Magdalini Migou, Irene Ghobrial

      Pages 73-82

   9. Waldenstrom’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment

      • D. E. Joshua, R. Brown, P. J. Ho, J. Gibson, H. Suen

      Pages 83-94

3. Epidemiology and Genetic Predisposition

   1. Front Matter

      Pages 95-95

      PDF

   2. Epidemiology of Waldenström Macroglobulinemia

      • Vilhjálmur Steingrímsson, Ola Landgren, Sigurður Yngvi Kristinsson

      Pages 97-109

   3. Genetic Predisposition to Waldenström Macroglobulinemia

      • Mary L. McMaster, Helga M. Ögmundsdóttir

      Pages 111-141

   4. Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)

      • Mary L. McMaster, Helga M. Ögmundsdóttir, Sigurdur Y. Kristinsson, Robert A. Kyle

      Pages 143-167

4. Clinical Features

   1. Front Matter

      Pages 169-169

      PDF

   2. Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia

      • Marvin J. Stone, Sigbjorn Berentsen

      Pages 171-183

   3. Neuropathy in Waldenström’s Macroglobulinaemia

      • Karine Viala, Michael Lunn

      Pages 185-194

   4. IgM Amyloidosis

      • Morie A. Gertz, Taimur Sher, Angela Dispenzieri, Francis K. Buadi

      Pages 195-207

   5. The Bing-Neel Syndrome

      • K. Ina Ly, Florian Fintelmann, Reza Forghani, Ephraim P. Hochberg, Fred H. Hochberg

      Pages 209-221

   6. Unusual Manifestations of IgM Monoclonal Gammopathies

      • Giampaolo Merlini, Bouchra Asli, Jean-Paul Fermand

      Pages 223-236

This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease.

Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.

• Chemotherapy
• Chronic disease
• Immunotherapy
• Lymphoma
• Monoclonal IgM
• Orphan disease

• Haematology, Hôpital Pitié-Salpêtriêre, Paris, France

  Véronique Leblond

• Dana Farber Cancer Institute, Boston, USA

  Steve Treon

• School of Medicine, University of Athens, Athens, Greece

  Meletios Dimoploulos

Véronique Leblond, Professor in Hematology, is the head of the department of Hematology at Pitié Salpêtrière Hospital, Paris, France. She is the chair of the “French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia: FCG CLL-WM” including more than 90 centers in France and Belgium. She is responsible for a rare tumor network (K-VIROGREF) dedicated to the management of transplant recipients with virus-induced tumors and funded by the French national Institute for cancer in 2012. The team historically focuses on chronic B-cell lymphoproliferative disorders, amyloidosis, on ocular and CNS lymphoma and on lymphoproliferations in immunosuppressed patients (HIV, organ-transplanted patients). She is the head of GRECHY, affiliated to the PhD school ED394 “Physiology & Physio-pathology”. Steven Treon is the Director of the Bing Center for Waldenström’s Research and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the University Athens School of Medicine, Athens, Greece. He is a member of numerous scientific societies and has authored more than 650 publications (April 2013) in peer-reviewed journals. Dr. Dimopoulos serves on the Scientific Advisory Boards of the Multiple Myeloma Research Foundation, of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is a member of the Board of the European Myeloma Network.

Policies and ethics